How does IMM's PB Ratio compare to its peers?

IMM is good value based on its Price-To-Book Ratio (2.2x) compared to the peer average (4.5x).

How does IMM's PB Ratio compare vs other companies in the AU Biotechs Industry?

IMM is good value based on its Price-To-Book Ratio (2.2x) compared to the Australian Biotechs industry average (3.1x).

What is IMM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate IMM's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of IMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate IMM's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Immutep (ASX:IMM) - Stock Price, News & Analysis

IMM Stock Overview

A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details

IMM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 52.52% per year

Analysts in good agreement that stock price will rise by 233.3%

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$4M)

Immutep Limited Competitors

Imugene

ASX:IMU

AU$297.5m

Clinuvel Pharmaceuticals

ASX:CUV

AU$669.3m

Dimerix

ASX:DXB

AU$186.6m

Mesoblast

ASX:MSB

AU$1.8b

Price History & Performance

Summary of all time highs, changes and price drops for Immutep
Historical stock prices
Current Share Price	AU$0.28
52 Week High	AU$0.48
52 Week Low	AU$0.23
Beta	1.92
11 Month Change	-5.00%
3 Month Change	-22.97%
1 Year Change	-3.39%
33 Year Change	-44.12%
5 Year Change	14.00%
Change since IPO	-90.50%

Recent updates

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19

Shareholder Returns

	IMM	AU Biotechs	AU Market
7D	-16.2%	-3.6%	1.5%
1Y	-3.4%	10.0%	17.2%

Return vs Industry: IMM underperformed the Australian Biotechs industry which returned 10% over the past year.

Return vs Market: IMM underperformed the Australian Market which returned 17.2% over the past year.

Price Volatility

Is IMM's price volatile compared to industry and market?
IMM volatility
IMM Average Weekly Movement	7.9%
Biotechs Industry Average Movement	9.7%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: IMM has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: IMM's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	n/a	Marc Voigt	www.immutep.com

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

Immutep Limited Fundamentals Summary

How do Immutep's earnings and revenue compare to its market cap?
IMM fundamental statistics
Market cap	AU$443.64m
Earnings (TTM)	-AU$42.72m
Revenue (TTM)	AU$3.84m

107.9x

P/S Ratio

-9.7x

P/E Ratio

Is IMM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMM income statement (TTM)
Revenue	AU$3.84m
Cost of Revenue	AU$41.55m
Gross Profit	-AU$37.70m
Other Expenses	AU$5.01m
Earnings	-AU$42.72m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.029
Gross Margin	-981.42%
Net Profit Margin	-1,111.87%
Debt/Equity Ratio	0.5%

How did IMM perform over the long term?

See historical performance and comparison

IMM Stock Overview

Rewards

Risk Analysis

Immutep Limited Competitors

ASX:IMU

AU$297.5m

ASX:CUV

AU$669.3m

ASX:DXB

AU$186.6m

ASX:MSB

AU$1.8b

Price History & Performance

Recent News & Updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Consensus revenue estimates increase by 64%

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Consensus revenue estimates increase by 64%

Consensus revenue estimates increase by 16%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

New minor risk - Shareholder dilution

No longer forecast to breakeven

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Price target increased by 8.1% to AU$0.97

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

New minor risk - Profitability

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Price target decreased by 29% to AU$0.90

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 54%

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Consensus EPS estimates upgraded to AU$0.024 loss

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Consensus EPS estimates fall by 58%

Immutep Limited, Annual General Meeting, Oct 24, 2023

Consensus revenue estimates decrease by 77%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to AU$0.052 loss

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 23%

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Consensus revenue estimates increase by 19%

Price target increased by 15% to AU$1.33

No longer forecast to breakeven

Consensus revenue estimates increase by 20%

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Consensus forecasts updated

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease